BGI Genomics (SHE:300676) secured the approval of China's drug regulator for changes to its NIFTY prenatal testing kit.
The changes add the NIFTY-B model and expand instrument compatibility to include the DNBSEQ-G99 sequencer, according to a Thursday filing with the Shenzhen bourse. The kit is used to screen for fetal chromosomal abnormalities.
Shares of the genomics services provider closed 5% lower Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments